$LPCN News
Last published 1d ago
- 1d agoLPCNLipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum DepressionPR NewswireLipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that...
- 6d agoLPCNLipocine Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1mo agoLPCNLipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement TherapyPR NewswireLipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through ...
- 1mo agoLPCNLipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum DepressionPR NewswireLipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced the...
- 2mo agoLPCNLipocine to Present at the H.C. Wainwright 28th Annual Global Investment ConferencePR NewswireLipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company...
- 3mo agoLPCNLipocine Announces Financial Results for the Second Quarter Ended June 30, 2026PR NewswireLipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial...
- 3mo agoLPCNAPREACETLipocine Appoints Michael J. Grissinger to Board of DirectorsPR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 5mo agoLPCNLipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154PR NewswireLipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that it will...
- 5mo agoLPCNLipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual MeetingPR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 5mo agoLPCNAnaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business OfficerGlobeNewswireBASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases,
- 5mo agoLPCNLipocine to Present at A.G.P.'s Annual Virtual Healthcare Company ShowcasePR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 6mo agoLPCNLipocine Announces Financial Results for the First Quarter Ended March 31, 2026PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 7mo agoLPCNLipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum DepressionPR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...
- 8mo agoLPCNLipocine Announces Financial Results for the Full Year Ended December 31, 2025PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 8mo agoLPCNLipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...
- 9mo agoLPCNLipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...
- 9mo agoCGCDFTXKDPLPCN2026 Asset Growth: Why Federal Compliance Is the New MetricGlobeNewswireVANCOUVER, British Columbia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Consumer healthcare markets hit a massive $362 billion entering 2026, but smart money is shifting toward regulatory
- 10mo agoLPCNLipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...
- 11mo agoLPCNLipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment MilestonePR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...
- 11mo agoLPCNLipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...
- 1y agoLPCNLipocine Announces Financial Results for the Third Quarter Ended September 30, 2025PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 1y agoLPCNLipocine Presents LPCN 2401 Clinical Data at ObesityWeek®PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...
- 1y agoLPCNLipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...
- 1y agoLPCNLipocine to Present at H.C. Wainwright 27th Annual Global Investment ConferencePR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...
- 1y agoLPCNLipocine Inc. - Appeal, Rehearing Decision â GrantedUS Patent Trial and Appeal Board
- 1y agoLPCNLipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...
- 1y agoLPCNLipocine Announces Financial Results for the Second Quarter Ended June 30, 2025PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...
- 1y agoLPCNLipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum DepressionPR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...
- 1y agoLPCNLipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of...
- 1y agoLPCNLipocine Announces Filing of New Drug Submission for TLANDO® in CanadaPR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of...
- 1y agoLPCNLipocine's LPCN 1148 Highlighted in the June 2025 Edition of HepatologyPR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 1y agoLPCNLipocine to Present at A.G.P.'s Annual Healthcare Company ShowcasePR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 1y agoLPCNLipocine Announces Financial Results for the First Quarter Ended March 31, 2025PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 1y agoLPCNLipocine Announces License and Supply Agreement for TLANDO® in BrazilPR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of...
- 1y agoLPCNLipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of...
- 1y agoLPCNLipocine Announces Financial Results for the Full Year Ended December 31, 2024PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 1y agoLPCNLipocine Announces FDA Labeling Changes for Testosterone ProductsPR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 1y agoLPCNLipocine Receives Updated Regulatory Guidance on LPCN 1154PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 1y agoLPCNLipocine Inc. - Appeal, Affirmed with New Ground of RejectionUS Patent Trial and Appeal Board
- 1y agoLPCNFDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated CirrhosisPR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 1y agoLPCNLipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut SessionPR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 2y agoLPCNLipocine Announces Financial Results for the Third Quarter Ended September 30, 2024PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 2y agoLPCNLipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South KoreaPR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 2y agoLPCNLipocine Announces Positive Oral Brexanolone Quantitative EEG ResultsPR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 2y agoLPCNLipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) CountriesPR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 2y agoLPCNLipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 2y agoLPCNLipocine to Present at H.C. Wainwright 8th Annual MASH Investor ConferencePR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 2y agoLPCNLipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®PR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 2y agoLPCNLipocine Inc. - Appeal, ReversedUS Patent Trial and Appeal Board
- 2y agoLPCNLipocine to Present at H.C. Wainwright 26th Annual Global Investment ConferencePR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...